1 – 10 of 69
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance
- Contribution to journal › Article
-
Mark
Optimizing peptide nucleic acid-based pretargeting for enhanced targeted radionuclide therapy
- Contribution to journal › Article
-
Mark
Prostate-specific antigen levels at age 60 and lifetime risk of lethal prostate cancer
(2025) In Journal of the National Cancer Institute
- Contribution to journal › Article
- 2024
-
Mark
Impact of site-specific conjugation strategies on the pharmacokinetics of antibody conjugated radiotherapeutics
- Contribution to journal › Article
-
Mark
Beyond Average : a-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer
- Contribution to journal › Article
- 2023
-
Mark
Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response
- Contribution to journal › Article
- 2022
-
Mark
Prostate cancer polygenic risk score and prediction of lethal prostate cancer
- Contribution to journal › Article
- 2021
-
Mark
Improved 223Ra Therapy with Combination Epithelial Sodium Channel Blockade
- Contribution to journal › Article
-
Mark
PSA-Targeted Alpha-, Beta-, and Positron-emitting immunotheranostics in murine prostate cancer models and nonhuman primates
- Contribution to journal › Article
- 2020
-
Mark
Preclinical Single Photon Emission Computed Tomography of Alpha Particle-Emitting Radium-223
- Contribution to journal › Article
